24th week of 2011 patent applcation highlights part 57 |
Patent application number | Title | Published |
20110144117 | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin - Pharmaceutical dosage form comprising tetrahydrobiopterin, or a metabolic precursor thereof, comprising an aqueous solution of tetrahydrobiopterin, or a metabolic precursor thereof, and an antioxidant in a dispensing container and a dosing means for the dosed dispensation of the aqueous solution, as well as the use of an antioxidant for stabilizing an aqueous solution of tetrahydrobiopterin, or a metabolic precursor thereof, for a storage period of more than at least one month. | 2011-06-16 |
20110144118 | ANTIVIRAL SALTS - This invention relates to antiviral agents, in particular to salts useful in the treatment of infections caused by Picornaviridae, such as human rhinovirus (HRV) and methods for their preparation. The invention also relates to the use of these salts in the treatment of picornavirus infections. The salts of this invention are especially suitable for use in the treatment of HRV, however it is to be understood that the invention is also applicable to other viruses of the picornavirus family. | 2011-06-16 |
20110144119 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH - The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease. | 2011-06-16 |
20110144120 | PHENYL-ALKYL PIPERAZINES HAVING TNF-MODULATING ACTIVITY, PREPARATION METHOD, AND THERAPEUTIC USE THEREOF - The present invention relates to phenyl-alkyl piperazines of formula (I): | 2011-06-16 |
20110144121 | BICYCLIC PYRAZOLO-HETEROCYCLES - The present invention provides substituted pyrazolo-heterocycles having the general structure of formula I | 2011-06-16 |
20110144122 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME - The present invention relates to derivatives of 4-{2-[phenyl-3,6-dihydropyridin-1-yl]-2-oxoalkyl}-1-piperazin-2-one and 4-{2-[phenyl-2,5-dihydropyrrol-1-yl]-2-oxoalkyl}-1-piperazin-2-one having general formula (I): | 2011-06-16 |
20110144123 | Thiazoles and Oxazoles Useful as Modulators of ATP-Binding Cassette Transporters - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2011-06-16 |
20110144124 | Compounds and Compositions for Use as Modulators of Tau Aggregation and Alleviation of Tauopathies - This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia. | 2011-06-16 |
20110144125 | Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore - The disclosure describes an animal model for simulating cardiac arrhythmia. Methods of discovering new anti-arrhythmia drugs using the model are described. Novel anti-arrhythmia agents are provided, as are pharmaceutical compositions made from the agents. Methods of inhibiting spontaneous mechanical activity in myocardially-derived biological systems, and methods of treating and preventing cardiac arrhythmia based on novel anti-arrhythmia agents are described. Kits for performing the above methods are also described. | 2011-06-16 |
20110144126 | COMPOUNDS USEFUL FOR INHIBITING CHK1 - The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof or a solvate of the salt, that inhibits Chk1 and is useful in the treatment of cancer. | 2011-06-16 |
20110144127 | AGENTS FOR TREATMENT OF GLAUCOMATOUS RETINOPATHY AND OPTIC NEUROPATHY - Agents that stimulate nuclear translocation of Nrf2 protein and the subsequent increases in gene products that detoxify and eliminate cytotoxic metabolites are provided in a method for treating glaucomatous retinopathy or optic neuropathy. The structurally diverse agents that act on the Nrf2/ARE pathway induce the expression of enzymes and proteins that possess chemically versatile cytoprotective properties and are a defense against toxic metabolites and xenobiotics. Agents include certain electrophiles and oxidants such as a Michael Addition acceptor, diphenol, thiocarbamate, quinone, 1,2-dithiole-3-thione, butylated hydroxyanisole, flavonoid, an isothiocyanate, 3,5-di-tert-butyl-4-hydroxytoluene, ethoxyquin, a coumarin, combinations thereof, or a pharmacologically active derivative or analog thereof. | 2011-06-16 |
20110144128 | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands - Heterocyclic carboxamide compounds are described herein as being useful in modulating the activity of steroid nuclear receptors. Pharmaceutical compositions containing the compounds, methods of using the compounds and processes for making the compounds are also described. | 2011-06-16 |
20110144129 | 3-Aminocyclopentanecarboxamides as Chemokine Receptor Agonists - There is provided a compound of Formula I(a) or I(b) | 2011-06-16 |
20110144130 | Use of 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-p- enta-2,4-dienoic acid as a cosmetic - The invention relates to 5-(7-methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methyl-penta-2,4-dienoic acid and its use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said compound. | 2011-06-16 |
20110144131 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES - The invention relates to substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias. | 2011-06-16 |
20110144132 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES - A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 2011-06-16 |
20110144133 | SUBSTITUTED PYRIMIDONE DERIVATIVES - Pyrimidone derivatives of formula (I) | 2011-06-16 |
20110144134 | Anti-Inflammatory Pyrazolopyrimndines - The present invention provides anti-inflammatory compounds useful in the treatment of diseases and conditions in which inflammation is involved in disease progression or the manifestation of symptoms of the disease or condition. | 2011-06-16 |
20110144135 | Compounds for Modulating TRPV3 Function - The present application relates to compounds and methods for treating pain and other conditions related to TRPV3. | 2011-06-16 |
20110144136 | NOVEL ADENINE DERIVATIVES - The present invention relates to compounds of formula (I): | 2011-06-16 |
20110144137 | METHOD FOR PREVENTING OR ALLEVIATING THE NOXIOUS EFFECTS RESULTING FROM TOXICANT EXPOSURE - The present invention provides a method of using agents which can modulate TRPA1 function as counteragents to inhibit the physical effects of chemical irritants/toxicants when given prior to exposure or to lessen the physical effects when administered post exposure, and more specifically, to a method for counteracting the acute physical noxious effects of toxicants, including but not limited to, tear gases, chlorine, hydrogen peroxide, ammonia, phosgene, chloropicrin, isocyanates and mustard gas. Administering the counteragents counteracts pain, inflammation, lachrymation, blepharospasm, respiratory irritation and depression, airway mucus secretion, airway obstruction and injury, cough and incapacitation and cutaneous chemical injuries. Another embodiment provides a method of preventing or treating a disease or condition in a mammal, which disease or condition includes hypersensitivity to chemical stimuli, particularly in regards to inflammatory airway conditions, such as asthma, rhinitis, etc., by administering to the mammal a therapeutically effective amount of a compound that inhibits TRPA1 function, wherein the compound reduces the hypersensitivity and mediates the response to such chemical stimuli in the mammal. The invention also includes a kit containing the compound that inhibits the TRPA1 function as a counteracting agent for administration prior to or post exposure to prevent or limit the effects of the exposure. | 2011-06-16 |
20110144138 | SUBSTITUTED PYRIMIDO ISOQUINOLINE DERIVATIVES - Pyrimido isoquinoline derivatives represented by formula (I): | 2011-06-16 |
20110144139 | HEPSIN INHIBITORS - Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors. | 2011-06-16 |
20110144140 | PYRIDINYL-PYRIMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATING AGENTS - This invention relates to novel pyridinyl-pyrimidine derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels. | 2011-06-16 |
20110144141 | Hair Growth and/or Regrowth Compositions - The present disclosure relates to compositions containing certain pyrimidine compounds such as minoxidil and/or certain pyrimidine sulfate (inner salt) compounds such as minoxidil sulfate and especially compositions containing pyrimidine compounds in combination with an admixtures comprising at least one antioxidant, at least one organic acid and a select fatty acid mixture. The present disclosure also relates to use of the compositions to grow and/or regrow hair and/or prevent hair loss in mammals and particularly in humans. | 2011-06-16 |
20110144142 | Methods of Reducing Hair Loss and/or Facilitating Hair Growth and/or Regrowth - The present disclosure relates to methods of retarding hair loss or facilitating hair growth and/or regrowth. More specifically, the present disclosure relates to methods of using the disclosed compositions to increase the rate of terminal hair growth and/or regrowth in a mammal. | 2011-06-16 |
20110144143 | PHARMACEUTICAL COMPOSITION CONTAINING FERULIC ACID AND MATRINE COMPOUNDS, THE PREPARATION AND THE USE THEREOF - Preparation and usage of a pharmaceutical composition containing ferulic acid and matrine compounds are described. The ingredients ferulic acid and matrine compounds in this pharmaceutical composition have synergistic effects which can obviously improve the pharmacology effects of both the ferulic acid and matrine compounds. Moreover, the pharmaceutical composition can significantly increase the aqueous and fat solubility of the individual ingredients. | 2011-06-16 |
20110144145 | METHODS FOR TREATING VISCERAL FAT CONDITIONS - Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion. | 2011-06-16 |
20110144146 | Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor - The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula I | 2011-06-16 |
20110144147 | INJECTABLE PHARMACEUTICAL COMPOSITIONS OF AN ANTHRACENEDIONE DERIVATIVE WITH ANTI-TUMORAL ACTIVITY - Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride. | 2011-06-16 |
20110144148 | ACETYLCHOLINESTERASE DUAL INHIBITORS - The invention provides compounds of formula: | 2011-06-16 |
20110144149 | GEMIFLOXACIN PROCESS AND POLYMORPHS - The present invention provides a novel process for the preparation of gemifloxacin and its pharmaceutically acceptable acid addition salts in high yield. The present invention also relates to novel polymorphs of gemifloxacin free base and its hydrates to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention also relates to infusion solutions of gemifloxacin and to processes for their preparation. Thus, 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphth-yridine-3-carboxylic acid is reacted with a mixture of acetic anhydride, acetic acid and boric acid to give borane compound, which is then treated with 4-Aminomethyl-3-methoxyimino-pyrrolidinium dimethanesulfonate in presence of triethylamine, followed by treatment with 3.5% sodium hydroxide solution to give gemifloxacin free base. | 2011-06-16 |
20110144150 | BRIDGED BICYCLIC RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE - The present invention is directed to synthetic bridged bicyclic compounds that are inhibitors of rho-associated protein kinase. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with cytoskeletal reorganization. The method comprises administering to a subject a therapeutically effective amount of a Rho kinase inhibitory compound of Formula I, wherein said amount is effective to influence the actomyosin interactions, for example, by leading to cellular relaxation and alterations in cell-substratum adhesions. In one embodiment, the method treats increased intraocular pressure, such as primary open-angle glaucoma. In another embodiment, the method treats diseases or conditions of the lung associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. | 2011-06-16 |
20110144151 | NOVEL PROCESS, SALTS, COMPOSITION AND USE - The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy. | 2011-06-16 |
20110144153 | AMIDE COMPOUND - [Problems] A compound, which is useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating chronic renal failure and/or diabetic nephropathy, is provided. | 2011-06-16 |
20110144154 | Salts of 2-Substituted Quinolines - The invention relates to salts of 2-substituted quinolines, the manufacturing method for same, and use of the same for the production of drugs. Said salts are advantageous in that the same can be obtained in crystalline form, which facilitates their implementation in the manufacture of pharmaceutical compositions. | 2011-06-16 |
20110144155 | 8-HYDROXYQUINOLINE DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES - The application relates to compositions and methods for treating hematological malignancies and proliferative diseases, disorders and conditions involving increased D-cyclin expression. In particular, the application relates to compositions and methods for treating the hematological malignancies acute myeloid leukemia (AML), lymphoma and multiple myeloma (MM) using 5-nitrogen substituted hydroxy quinolones as well as 7-bromo-5-chloro substituted hydroxy quinolones and 5-chloro substituted hydroxy quinolones. | 2011-06-16 |
20110144156 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS - Provided are 2,4-disubstituted quinoline derivatives that are A3 adenosine receptor modulators (A | 2011-06-16 |
20110144157 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF - The subject of the invention is Compound of Formula (I): | 2011-06-16 |
20110144158 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - This invention relates to isoindole-imide compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed. | 2011-06-16 |
20110144159 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS - The present invention relates to compounds of Formula (I) wherein Ar is optionally substituted phenyl or 6-membered heteroaryl moiety, or a benzisoxazole, pyrrolopyridine, or benzotriazole group; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity, including pain, urinary incontinence, overactive bladder, emesis, cognitive disorders, anxiety, depression, sleeping disorders, eating disorders, movement disorders, glaucoma, psoriasis, multiple sclerosis, cerebrovascular disorders, brain injury, gastrointestinal disorders, hypertension, or cardiovascular disease. | 2011-06-16 |
20110144160 | Antagonists of Prostaglandin D2 Receptors - Described herein are compounds that are antagonists of PGD | 2011-06-16 |
20110144161 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS - The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R | 2011-06-16 |
20110144162 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE - The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof. | 2011-06-16 |
20110144163 | THIOLATED PACLITAXELS FOR REACTION WITH GOLD NANOPARTICLES AS DRUG DELIVERY AGENTS - Thioloated taxane derivatives are linked to colloidal metal particles such as gold nanoparticles for use as antitumor agents. The antitumor agents may be targeted to tumors. | 2011-06-16 |
20110144164 | Pyridone derivatives as NK3 antagonists - The present invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds. | 2011-06-16 |
20110144165 | PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS - The present invention provides for compounds of formula (I) | 2011-06-16 |
20110144166 | HIGH CONCENTRATION TOPICAL INSECTICIDES CONTAINING PYRETHROIDS - A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth regulator (IGR). The topical insecticide preparation can be packaged together or packaged so that the first and second pyrethroid insecticides are stored separately prior to administration of the insecticide preparation to the animal. The combination of the first and second pyrethroid insecticides with an insect growth regulator results in an insecticide preparation formulated to have enhanced insecticidal activity against fleas and ticks compared to the effectiveness of the first and second insecticides used alone. Further, the combination of the first and second pyrethroid insecticides with an insect growth regulator produces an insecticide preparation having enhanced insecticidal activity against fleas and ticks while advantageously minimizing the total amount of insecticide needed for its effectiveness. | 2011-06-16 |
20110144167 | Prolyl Hydroxylase Inhibitors - The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) | 2011-06-16 |
20110144168 | OXAZOLIDINE DERIVATIVES AS NMDA ANTAGONISTS - The present invention provides therapeutically active oxazolidine derivatives and compositions as NMDA antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, and methods of enhancing the brain's cognitive functions in mammals and humans. For example, the compounds can prevent glutamate-induced neuro-toxicity by inhibiting the activities of the NMDA receptor in the presence of toxic doses of NMDA. In addition, the compounds can potentiate the calcium current in the presence of low dose of NMDA. | 2011-06-16 |
20110144169 | Inhibitors of cellular necrosis - The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis. | 2011-06-16 |
20110144170 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS - The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl zing substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the FcγRIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor. | 2011-06-16 |
20110144171 | THIOPENE CONTAINING ANALOGUES OF FLUCONAZOLE AS ANTIFUNGAL AGENTS AND PROCESS FOR THEIR PREPARATION - The present invention discloses novel compounds of the Formula (1), containing thiophene moieties and pharmaceutically acceptable salts thereof, methods for preparing these compounds, the use of these compounds in prevention and treatment of fungal infections, and pharmaceutical preparations containing these novel compounds. | 2011-06-16 |
20110144172 | Crystalline Modifications of Prothioconazole - There is disclosed a crystalline DMSO solvate of prothioconazole as well as amorphous prothioconazole. Methods for making these solid forms, microbicidal compositions comprising them and uses thereof are also disclosed. | 2011-06-16 |
20110144173 | FUNGICAL CONTROL OF MOULDS - A composition for treating fungus infection of turfgrass, such as snow mould infection, comprises a mixture of fungicidally effective amounts of formulae 1 and 2: | 2011-06-16 |
20110144174 | DEUTERIUM-ENRICHED ODANSETRON - The present application describes deuterium-enriched ondansetron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2011-06-16 |
20110144175 | METHOD FOR CONTROLLING DEGRADATION OF AGRICULTURAL CHEMICAL ACTIVE INGREDIENT - When Cyazofamid is formulated in accordance with a conventional formulation method, Cyazofamid is degraded in some cases. The problem to be solved by the present invention is to improve storage stability of the formulation by controlling degradation of Cyazofamid as an agricultural chemical active ingredient. The present invention provides a method for controlling degradation of an agricultural chemical active ingredient, Cyazofamid, which comprises using at least one stabilizer selected from the group consisting of epoxidized animal oil and/or vegetable oil, a nonionic surface active agent of polyoxyethylene, an anionic surface active agent of polyoxyethylene, polyhydric alcohol and a basic substance. | 2011-06-16 |
20110144176 | MACROLIDES AND METHODS FOR PRODUCING SAME - This invention relates, in part, to macrolide compounds, actinomycete strains for producing them, and pharmaceutical compositions containing them. | 2011-06-16 |
20110144177 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents - Carbamoyl esters inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. In one embodiment, the carbamoyl ester has the following structure: | 2011-06-16 |
20110144178 | 1 ,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS - The invention provides new compounds of formula (I) wherein R | 2011-06-16 |
20110144179 | Substituted Heterocyclic Mercaptosulfonamide Metalloprotease Inhibitors - The present invention generally relates to substituted heterocyclic mercaptosulfonamide compounds, precursors, and derivatives as well as methods for the preparation of and pharmaceutical compositions comprising these compounds. These compounds are designed to be potent selective inhibitors of matrix metalloproteinases (MMPs), including, for example, gelatinases, collagenases, matrilysins, metalloelastase, stromelysin, and membrane-type 1 matrix metalloproteinase. These inhibitors may be used for the control of physiological and pathological processes and disease conditions in which MMPs are believed to play significant functions. | 2011-06-16 |
20110144180 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 2011-06-16 |
20110144181 | Pharmaceutical Compositions of Amorphous Atorvasta and Process for Preparing Same - Solid pharmaceutical compositions containing atorvastatin are disclosed. The compositions include a solid dispersion of amorphous atorvastatin and one or more optional pharmaceutically acceptable excipients. The solid dispersion is prepared by mixing crystalline atorvastatin with a melt-processible polymer and an optional stabilizer and an optional plasticizer at a temperature sufficiently high to soften or melt the polymer and to melt or dissolve the crystalline atorvastatin in the polymer, thereby forming a dispersion of amorphous atorvastatin. | 2011-06-16 |
20110144182 | TREATMENT OF SURGICAL ADHESIONS - Connexin modulation for the treatment of surgical adhesions, and associated methods, compositions, and articles. | 2011-06-16 |
20110144183 | OLIGONUCLEOTIDES FOR TREATING INFLAMMATION AND NEOPLASTIC CELL PROLIFERATION - There is provided oligonucleotides directed against the CCR3 receptor and the common beta sub-unit of IL-3, IL-5 and GM-CSF receptors. The oligonucleotides are useful to inhibit general inflammation, including inflammation associated with asthma, COPD, allergy, Cystic fibrosis (CF), hypereosinophilia and neoplastic cell proliferation such as cancer. | 2011-06-16 |
20110144184 | PREVENTING OR TREATING VIRAL INFECTION USING AN INHIBITOR OF THE LSD1 PROTEIN, A MAO INHIBITOR OR AN INHIBITOR OF LSD1 AND A MAO INHIBITOR - An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV). The viral infection may also be due to an adenovirus, including types 1-5. | 2011-06-16 |
20110144185 | RNA ANTAGONISTS TARGETING HSP27 - The present invention relates to oligomer compounds (oligomers), which target Hsp27 mRNA in a cell, leading to reduced expression of Hsp27. Reduction of Hsp27 expression is beneficial for the treatment of certain medical disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of Hsp27 using said oligomers, including methods of treatment | 2011-06-16 |
20110144186 | SSX-2 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES - The invention describes HLA class II binding peptides encoded by the SSX-2 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4 | 2011-06-16 |
20110144187 | APTAMER INHIBITION OF THROMBUS FORMATION - Boronic acid-modified DNA-based aptamers can be selected to recognize fibrinogen through binding at a glycosylation site and thus are useful for probing the effect of glycosylation pattern changes on the ability for fibrinogen to mediate blood coagulation. In addition, the aptamers of the disclosure also have anticoagulation effects due to their binding to fibrinogen and its cleavage product fibrin. The present disclosure, therefore, encompasses methods for inhibiting fibrin coagulation with an aptamer capable of specifically binding to a glycosylation site of fibrinogen or fibrin. The disclosure further provides oligonucleotide aptamers comprising at least one nucleotide having a boronic acid thereon, where the aptamer is capable of selectively binding to a glycosylation site of fibrinogen, or the derivative thereof. | 2011-06-16 |
20110144188 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE - Unique salts of trimebutine and N-monodesmethyl trimebutine, and their corresponding stereoisomers, having improved analgesic properties useful in the treatment of visceral pain are provided. The salts of the present invention are particularly useful in the treatment of conditions characterized by abdominal pain, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), diabetic gastroparesis, and dyspepsia. | 2011-06-16 |
20110144189 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING - The present invention relates to compounds having the formula: | 2011-06-16 |
20110144190 | METHOD OF PREPARING A SUPRAMOLECULAR COMPLEX CONTAINING A THERAPEUTIC AGENT AND A MULTI-DIMENSIONAL POLYMER NETWORK - A method of preparing a supramolecular complex containing at least one therapeutic agent and a multi-dimensional polymer network is described. A supramolecular complex prepared by a method of the invention is described. A method of treatment by administering a therapeutically effective amount of a supramolecular complex of the invention is also described. Such a supramolecular complex may be used as a delivery vehicle for various therapeutic agents. | 2011-06-16 |
20110144191 | COMPOSITIONS COMPRISING TERPENE COMPOUNDS FOR TREATING NEGATIVE SENSORY PHENOMENA - Compositions comprising terpene compounds for the treatment of negative sensory phenomena (NSP). Negative sensory phenomena is characterized by a decreased ability to sense light touch, pin prick, vibration, temperature, pain and/or reduced proprioception. The terpene compounds are preferably aromatic terpene compounds such as geraniol and citronellol and analogs thereof. The terpenes may also be used in combination. The terpenes are derived form plant essential oils or are manufactured synthetically. | 2011-06-16 |
20110144192 | Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria - Method for modulating or controlling sodium channel current of a cell includes inducing mitochondrial reactive oxygen species (ROS) production in the cell. | 2011-06-16 |
20110144193 | Pharmaceutical Composition Comprising Cinchonains Ia And Ib, Process For Preparing An Epimeric Mixture Of Cinchonains Ia And Ib, Use And Method For Reverting/Combating Ventricular Fibrillation - The present invention relates to the effects of the epimeric mixture of cinchonains Ia and Ib on pathologies that involve alterations in the cardiovascular system, essentially in combating, preventing and reverting ventricular fibrillation in human beings and animals, especially for combating spontaneous or electric-stimulus-induced ventricular fibrillation, to revert spontaneous or electric-stimulus-induced ventricular fibrillations, for preventing ventricular fibrillation, for the treatment of ventricular fibrillation of any etiology or for the treatment of post-fibrillation to maintain normal cardiac rhythm. | 2011-06-16 |
20110144194 | CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - Compounds of general formula (I) and (II) in which R | 2011-06-16 |
20110144195 | METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF - Two distinct methods are disclosed and claimed for synthesizing glyceollin I plus glyceollin II as a mixture and as their pure forms. Stereochemical isomers and various synthetic intermediates are also synthesized and claimed for their novel compositions of matter. All compounds and their mixtures are claimed for use in formulations that are useful to treat or prevent cancer, or that have utility as selective estrogen receptor modulators, such formulations including enhanced or medical foods, dietary supplements and ethical pharmaceutical agents. | 2011-06-16 |
20110144196 | TREATING VARIOUS DISORDERS WITH 7,8-DIHYDROXYFLAVONE AND DERIVATIVES THEREOF - Novel compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof. Specifically, methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. A further method of promoting neuroprotection in a subject also is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. | 2011-06-16 |
20110144197 | ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES - Compounds of the general formula (formula I) | 2011-06-16 |
20110144198 | BREAST CANCER PROGNOSTICS - The present invention provides new methods, uses and means for breast cancer prognostics. The provided method for establishing a prognosis for a mammalian subject having a breast cancer, comprises the steps of: obtaining a hormone receptor status of the subject; obtaining an HMGCR protein value of the subject; and correlating the hormone receptor status and the HMGCR protein of the subject to a prognosis for the subject. | 2011-06-16 |
20110144199 | METHODS FOR TREATING ATRIAL FIBRILLATION - The subject invention provides methods for reducing atrial fibrillation (AF) episode duration, methods for reducing stroke rate, methods for increasing time in normal sinus rhythm (NSR), methods for preventing atrial remodeling, and methods for reversing atrial remodeling, all comprising administering an amount of budiodarone effective to reduce AF episode duration. | 2011-06-16 |
20110144200 | COMBINATION OF CAROTENOIDS AND EPI-LUTEIN - The invention describes the preparation and use of carotenoid and epi-lutein compositions to treat various ocular diseases. | 2011-06-16 |
20110144201 | METHOD FOR IMPROVING THE TOLERANCE OF CROPS TO CHILLING TEMPERATURES AND/OR FROST - The present invention relates to the use of propamocarb and derivatives thereof for improving the tolerance of crops to chilling temperatures and/or frost. | 2011-06-16 |
20110144202 | CONCENTRATED OXALIPLATIN SOLUTION AND ITS METHOD OF PREPARATION - The present invention relates to a pharmaceutically stable and highly concentrated aqueous oxaliplatin solution. The present invention also concerns a method for preparing said solution. | 2011-06-16 |
20110144203 | Use Of Cationic Surfactants As Sporicidal Agents - Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the treatment of objects which are infected with spores. The spores may originate from bacteria or fungi. | 2011-06-16 |
20110144204 | BUFFER SOLUTIONS HAVING SELECTIVE BACTERICIDAL ACTIVITY AGAINST GRAM NEGATIVE BACTERIA AND METHODS OF USING SAME - Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided. | 2011-06-16 |
20110144205 | Blood Glutathione as a Biomarker for Screening Asymptomatic Patients at Risk for Heart Failure - The present invention relates to a method for screening an asymptomatic patient at risk for heart failure, said method comprising measuring the concentration of glutathione in a blood sample obtained from said patient. | 2011-06-16 |
20110144206 | USE OF A COX-2 INHIBITOR FOR THE TREATMENT OF A COX-2 DEPENDENT DISORDER IN A PATIENT NOT CARRYING HLA ALLELES ASSOCIATED WITH HEPATOTOXICITY - This disclosure relates to a method of determining the presence of at least one HLA allele, preferably selected from the group consisting of DQA1*0102, DRB1*1501, DQB1*0602 and DRB5*0101 to assess whether a patient is at risk for developing hepatotoxicity upon administration of the COX-2 inhibitor lumiracoxib. Also disclosed is the use of a kit for carrying out this method. The disclosure also relates to a method of treating cyclooxygenase-2 dependent disorders with lumiracoxib in a subject that is not a carrier of one or more HLA alleles, preferably selected from the group consisting of DQA1*0102, DRB1*1501, DQB1*0602 and DRB5*0101. | 2011-06-16 |
20110144207 | ARYL ALKYL CARBOXYLIC ACID SALTS, PROCESS FOR PREPARATION AND DOSAGE FORMS - The invention particularly discloses a process for preparing aryl alkyl carboxylic acid salts by preparing aqueous alkali solution, adding aryl alkyl carboxylic acid to said alkali solution at a temperature ranging from 4° to 121° C. for obtaining a clear solution, preferably by heating and/or stirring and concentrating and cooling to obtain aryl alkyl carboxylic acid salt The invention therefore discloses solid oral dosage forms and compositions of aryl alkyl carboxylic acid salts which are free of organic solvent/so. The solid oral dose compositions of aryl alkyl carboxylic acid salts of the invention are prepared in situ from aryl alkyl carboxylic acids and bases to obtain aryl acid alkyl carboxylic acid sails in crystalline/powder form with or without the use of pharmaceutical excipients. | 2011-06-16 |
20110144208 | COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE BIS-UREA DERIVATIVE - The present disclosure relates to cosmetic compositions comprising at least one continuous liquid fatty phase comprising at least one compound of formula (I), | 2011-06-16 |
20110144209 | USE OF VASOCONSTRICTORS - There is disclosed the topical dermal use of vasocontrictor substances for regulating body temperature to treat cancer by inducing hyperthermia and treat, prevent or delay the onset of anesthetic induced hypothermia. Kits containing appropriate materials and instructions, and other embodiments, are also disclosed. | 2011-06-16 |
20110144210 | STABLE DOSAGE FORMS OF LEVOMILNACIPRAN - The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described. | 2011-06-16 |
20110144211 | USE OF MICROCRYSTALLINE CELLULOSE FOR INTERFERING WITH THE EXTRACTION OF EPHEDRINE - Use of microcrystalline cellulose and, optionally, a surfactant in an aqueous pharmaceutical composition in order to inhibit the extraction of ephedrine for the purpose of drug abuse. | 2011-06-16 |
20110144212 | KEY INTERMEDIATE FOR THE PREPARATION OF STILBENES, SOLID FORMS OF PTEROSTILBENE, AND METHODS FOR MAKING THE SAME - The present invention provides a scalable process for the preparation of stilbenes by (i) condensing 3,5-dialkylbenzyl phosphonates with 4′-O-tetrahydropyranyl benzaldehyde to get 3,5-alkyl-4′-O-tetrahydropyranyl Stilbene and (ii) deprotecting the obtained 3,5-Dialkyl-4′-O-tetrahydropyranylstilbene to yield stilbenes. The present invention also provides a novel intermediate 3,5-Dialkyl-4′-O-tetrahydropyranyl stilbene, which is a key intermediate for the synthesis of stilbenes such as Pterostilbene and Resveratrol. The present invention also provides characteristics of various solid forms of Pterostilbene, methods for their preparation, as well as dosage forms containing the same for administration to or consumption by humans. | 2011-06-16 |
20110144213 | ANHYDROUS DEPIGMENTING COMPOSITIONS COMPRISING A SOLUBILIZED PHENOLIC COMPOUND - Novel anhydrous dermatological depigmenting compositions, especially for topical application, contain, as pharmaceutical active agent, a phenolic compound dissolved in a fatty phase therefor. | 2011-06-16 |
20110144214 | HYDROALCOHOLIC GEL COMPOSITIONS FOR USE WITH DISPENSERS - A hydroalcoholic gel composition includes greater than about 40 weight percent of an alcohol, based upon the total weight of the alcoholic composition, a polyacrylate thickener, and an ester plug-preventing agent. The composition is suitable for use in dispensers, and exhibits reduced mis-directed output when the dispenser is actuated. | 2011-06-16 |
20110144215 | BRUISE AMELIORATION COMPOSITION AND METHOD OF USE - A bruise amelioration composition that can be applied for one hour to an affected site, such as a bruise, contusion or blister, in the form of a gel, liquid or adhesive bandage. The composition includes at least 40% by weight of glycerin and at least 2% by weight of primrose oil. Preferably, the composition includes a fragrance, such as peach oil and marjoram and 1% to 10% by weight of vitamins A, C, D, E and K. | 2011-06-16 |
20110144216 | COMPOSITIONS AND USES OF CIS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE - This invention relates to compositions, methods and systems having utility in numerous applications, and in particular, uses for compositions containing the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm), which has the following structure: | 2011-06-16 |
20110144217 | POLYMER WITH SALT GROUPS AND ANTIFOULING COATING COMPOSITION COMPRISING SAID POLYMER - A film-forming polymer with improved chemical stability in antifouling coating applications, said polymer bearing pendant to its backbone a salt of (i) a basic group with a first pK | 2011-06-16 |
20110144218 | Taste-Modified Consumable Products And Methods Of Preparation - A taste-modified consumable product, such as food product (including but not limited to fruit juice concentrates, fruit purées, and dairy products such as yogurt and ice cream), medical product, romance product, or entertainment product, comprising of a taste-modifying substance, such as extract from a miracle berry, and a method for production thereof. | 2011-06-16 |